Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CMML
MCID: CHR285
MIFTS: 65

Chronic Myelomonocytic Leukemia (CMML)

Categories: Blood diseases, Bone diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Chronic Myelomonocytic Leukemia

About this section

MalaCards integrated aliases for Chronic Myelomonocytic Leukemia:

Name: Chronic Myelomonocytic Leukemia 38 12 76 53 59 29 15
Leukemia, Myelomonocytic, Chronic 53 73
Myelomonocytic Leukemia, Chronic 13
Leukemia Myelomonocytic Chronic 55
Cmml 59

Characteristics:

Orphanet epidemiological data:

59
chronic myelomonocytic leukemia
Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Genetic diseases
Anatomical: Blood diseases Bone diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 34 33
Orphanet: 59  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0080188
NCIt 50 C3178
Orphanet 59 ORPHA98823
UMLS via Orphanet 74 C0023480
ICD10 via Orphanet 34 C93.1
MESH via Orphanet 45 D015477
ICD10 33 C93.1
UMLS 73 C0023480
Sources

Summaries for Chronic Myelomonocytic Leukemia

About this section
Disease Ontology : 12 A chronic leukemia characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.

MalaCards based summary : Chronic Myelomonocytic Leukemia, also known as leukemia, myelomonocytic, chronic, is related to juvenile myelomonocytic leukemia and mastocytosis, and has symptoms including fever, fatigue and night sweats. An important gene associated with Chronic Myelomonocytic Leukemia is ETV6 (ETS Variant 6), and among its related pathways/superpathways are Developmental Biology and Akt Signaling. The drugs Cyclophosphamide and Busulfan have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Chronic myelomonocytic leukaemia (CMML) is a type of leukaemia, which are cancers of the blood-forming... more...

Sources

Related Diseases for Chronic Myelomonocytic Leukemia

About this section

Diseases in the Chronic Myelomonocytic Leukemia family:

Juvenile Myelomonocytic Leukemia

Diseases related to Chronic Myelomonocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 172)
# Related Disease Score Top Affiliating Genes
1 juvenile myelomonocytic leukemia 31.8 CSF2 DNMT3A FLT3 JAK2 NF1 PDGFRB
2 mastocytosis 30.7 KIT PDGFRB TET2
3 myelodysplastic myeloproliferative cancer 30.7 ASXL1 CSF2 CSF3R JAK2 NF1 PTPN11
4 chronic neutrophilic leukemia 30.6 ASXL1 CSF3R SETBP1
5 refractory anemia 30.5 ASXL1 JAK2 RUNX1 TET2
6 leukemia, acute lymphoblastic 30.5 ETV6 FLT3 RUNX1
7 leukemia 30.3 CSF2 CSF3R ETV6 FLT3 JAK2 KIT
8 systemic mastocytosis 30.3 ASXL1 JAK2 KIT PDGFRB TET2
9 atypical chronic myeloid leukemia 30.2 ASXL1 CSF3R JAK2 PDGFRB RUNX1 SETBP1
10 acute leukemia 30.0 ETV6 FLT3 JAK2 KIT RUNX1
11 myelofibrosis 29.9 ASXL1 EZH2 FLT3 JAK2 KIT TET2
12 essential thrombocythemia 29.8 ASXL1 EZH2 JAK2 TET2
13 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 29.8 CSF1 ETV6 FLT3 KIT RUNX1
14 megakaryocytic leukemia 29.7 CSF2 JAK2 RUNX1
15 hypereosinophilic syndrome 29.7 CSF2 KIT PDGFRB
16 myeloma, multiple 29.7 CSF2 JAK2 KIT PTPN11
17 polycythemia vera 29.7 JAK2 KIT PDGFRB TET2
18 myelodysplastic syndrome 29.6 ASXL1 CSF1 CSF2 CSF3R DNMT3A ETV6
19 myeloid leukemia 29.5 CSF2 CSF3R DNMT3A ETV6 FLT3 JAK2
20 aplastic anemia 29.4 ASXL1 CSF1 CSF2 CSF3R FLT3 TET2
21 severe congenital neutropenia 29.4 CSF2 CSF3R JAK2 PTPN11
22 myeloproliferative neoplasm 29.4 JAK2 KIT PDGFRB PTPN11 TET2
23 leukemia, chronic myeloid 29.3 CSF2 CSF3R ETV6 FLT3 JAK2 KIT
24 leukemia, acute myeloid 29.0 ASXL1 CSF2 CSF3R DNMT3A ETV6 EZH2
25 pdgfrb-associated chronic eosinophilic leukemia 11.9
26 lymphocytic leukemia 10.4
27 thrombocytopenia 10.3
28 lymphoma 10.3
29 primary hypereosinophilic syndrome 10.3 ETV6 PDGFRB
30 b-cell childhood acute lymphoblastic leukemia 10.2 ETV6 RUNX1
31 myeloproliferative disorder, chronic, with eosinophilia 10.2 ETV6 PDGFRB
32 leukemia, chronic lymphocytic 2 10.2
33 leukemia, chronic lymphocytic 10.2
34 hematopoietic stem cell transplantation 10.2
35 dendritic cell tumor 10.2
36 leukemia, b-cell, chronic 10.2
37 adhesions of uterus 10.2 KDM6A PDGFRB
38 sarcoma 10.2
39 histiocytosis 10.2
40 leukemia, acute lymphoblastic 3 10.1 ETV6 FLT3 RUNX1
41 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.1 JAK2 PDGFRB
42 primary polycythemia 10.1 ASXL1 JAK2 TET2
43 myofibroma 10.1 ETV6 PDGFRB
44 sm-ahnmd 10.1 ASXL1 KIT TET2
45 graft-versus-host disease 10.1
46 purpura 10.1
47 vasculitis 10.1
48 blastic plasmacytoid dendritic cell 10.1
49 acute myeloblastic leukemia with maturation 10.1 FLT3 KIT
50 subacute myeloid leukemia 10.1 FLT3 JAK2 TET2

Graphical network of the top 20 diseases related to Chronic Myelomonocytic Leukemia:



Diseases related to Chronic Myelomonocytic Leukemia
Sources

Symptoms & Phenotypes for Chronic Myelomonocytic Leukemia

About this section

UMLS symptoms related to Chronic Myelomonocytic Leukemia:


fever, fatigue, night sweats

GenomeRNAi Phenotypes related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

26 (show all 49)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.5 EZH2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.5 KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.5 CSF3R
4 Increased shRNA abundance (Z-score > 2) GR00366-A-108 10.5 EZH2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.5 PTPN11
6 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.5 U2AF1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.5 PTPN11
8 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.5 SETBP1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.5 CSF3R
10 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.5 TOP1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.5 CSF3R TOP1 U2AF1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.5 CSF2 PTPN11
13 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.5 CSF3R SETBP1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.5 CSF1 PTPN11
15 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.5 KIT
16 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.5 KIT SETBP1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.5 TOP1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.5 CSF3R SETBP1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.5 CSF3R
20 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.5 SETBP1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.5 CSF1 CSF2 KIT
22 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.5 PTPN11
23 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.5 SETBP1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.5 CSF2 EZH2 PTPN11 SETBP1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.5 SETBP1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.5 CSF1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.5 CSF3R
28 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.5 CSF2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.5 EZH2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.5 EZH2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.5 KIT
32 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.5 EZH2
33 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.5 PTPN11
34 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.5 KIT
35 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.5 CSF1 PTPN11
36 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.5 CSF2 EZH2
37 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.5 CSF3R PTPN11
38 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.5 EZH2
39 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.5 EZH2
40 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.5 PTPN11
41 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10.5 SETBP1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.5 SETBP1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.5 EZH2
44 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.5 KIT U2AF1 SETBP1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-88 10.5 EZH2
46 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.5 KIT
47 Increased shRNA abundance (Z-score > 2) GR00366-A-90 10.5 CSF1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.5 KIT
49 Reduced mammosphere formation GR00396-S 9.17 CSF1 CSF3R DNMT3A ETV6 PTPN11 RUNX1

MGI Mouse Phenotypes related to Chronic Myelomonocytic Leukemia:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.51 ASXL1 CSF1 CSF2 CSF3R DNMT3A ETV6
2 hematopoietic system MP:0005397 10.47 ASXL1 CSF1 CSF2 CSF3R DNMT3A ETV6
3 endocrine/exocrine gland MP:0005379 10.46 ASXL1 CSF1 CSF2 CSF3R DNMT3A ETV6
4 growth/size/body region MP:0005378 10.45 ASXL1 CSF1 CSF2 DNMT3A ETV6 EZH2
5 immune system MP:0005387 10.44 ASXL1 CSF1 CSF2 CSF3R DNMT3A ETV6
6 homeostasis/metabolism MP:0005376 10.43 ASXL1 CSF1 CSF2 DNMT3A ETV6 EZH2
7 mortality/aging MP:0010768 10.43 ASXL1 CSF1 CSF2 CSF3R DNMT3A ETV6
8 cardiovascular system MP:0005385 10.37 CSF1 CSF2 CSF3R ETV6 EZH2 KDM6A
9 behavior/neurological MP:0005386 10.34 ASXL1 CSF1 CSF2 DNMT3A EZH2 HIP1
10 embryo MP:0005380 10.31 CSF2 DNMT3A ETV6 EZH2 JAK2 KDM6A
11 neoplasm MP:0002006 10.22 ASXL1 CSF2 ETV6 EZH2 FLT3 HIP1
12 integument MP:0010771 10.19 CSF1 CSF2 ETV6 EZH2 JAK2 KIT
13 craniofacial MP:0005382 10.18 ASXL1 CSF1 CSF2 KDM6A KIT NF1
14 nervous system MP:0003631 10.15 CSF1 CSF2 CSF3R DNMT3A EZH2 HIP1
15 liver/biliary system MP:0005370 10.13 ASXL1 CSF1 HIP1 JAK2 KIT NF1
16 muscle MP:0005369 10.09 CSF1 DNMT3A EZH2 HIP1 KDM6A KIT
17 normal MP:0002873 10 ETV6 EZH2 HIP1 JAK2 KDM6A KIT
18 no phenotypic analysis MP:0003012 9.97 CSF1 ETV6 EZH2 FLT3 KDM6A KIT
19 reproductive system MP:0005389 9.85 CSF1 CSF2 CSF3R DNMT3A HIP1 JAK2
20 respiratory system MP:0005388 9.56 CSF1 CSF2 HIP1 KDM6A KIT NF1
21 skeleton MP:0005390 9.44 ASXL1 CSF1 CSF2 EZH2 FLT3 HIP1
Sources

Drugs & Therapeutics for Chronic Myelomonocytic Leukemia

About this section

Drugs for Chronic Myelomonocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 424)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
2
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
3 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2353-33-5 451668
9
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 320-67-2 9444
10
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4 6253
11
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
12
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
13
Ofloxacin Approved Phase 3 82419-36-1 4583
14
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
15
Idarubicin Approved Phase 3,Phase 1,Phase 2,Not Applicable 58957-92-9 42890
16
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
17
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
18
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
19
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
20
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
21
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 50-24-8 5755
22
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 302-25-0
23
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 83-43-2 6741
24
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3,Phase 1,Not Applicable 2921-57-5
25
Lenalidomide Approved Phase 3,Phase 1,Phase 2 191732-72-6 216326
26
Melphalan Approved Phase 2, Phase 3,Phase 1,Not Applicable 148-82-3 4053 460612
27
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 38904 498142
28
Tacrolimus Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
29
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
30
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
31
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 50-02-2 5743
32
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 1177-87-3
33
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
34
Daunorubicin Approved Phase 3,Phase 1,Phase 2 20830-81-3 30323
35
Thioguanine Approved Phase 3 154-42-7 2723601
36
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
37
Acyclovir Approved Phase 3 59277-89-3 2022
38
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1 52-24-4 5453
39
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
40
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
41
Heparin Approved, Investigational Phase 3,Not Applicable 9005-49-6 772 46507594
42
Dalteparin Approved Phase 3 9005-49-6
43
Ondansetron Approved Phase 3,Phase 2,Phase 1,Not Applicable 99614-02-5 4595
44
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
45
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
46
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
47
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
48
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 93-14-1 3516
49
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
50
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826

Interventional clinical trials:

(show top 50) (show all 492)
# Name Status NCT ID Phase Drugs
1 Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Not yet recruiting NCT01339988 Phase 4 Busulfan/Cyclophosphamide
2 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
3 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
4 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
5 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
6 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Unknown status NCT00002926 Phase 3 cytarabine;etoposide;idarubicin
7 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
8 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
9 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
10 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
11 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
12 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
13 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
14 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
15 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
16 Decitabine Versus Supportive Care in Adults With Advanced-stage MDS Completed NCT00043381 Phase 3 decitabine (5-aza-2'deoxycytidine)
17 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
18 S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia Completed NCT00005866 Phase 3 busulfan;cyclophosphamide;cyclosporine;methotrexate
19 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
20 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
21 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
22 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
23 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
24 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
25 Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
26 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
27 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
28 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
29 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
30 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
31 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
32 Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3 TBI, systemic chemotherapy and antibodies as follows:
33 Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Completed NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
34 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
35 Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) Recruiting NCT03268954 Phase 3 Azacitidine;Pevonedistat
36 Study of ASTX727 vs IV Decitabine in MDS and CMML Recruiting NCT03306264 Phase 3 ASTX727;Dacogen
37 Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML Recruiting NCT02214407 Phase 3 Decitabine;HYDROXYUREA
38 Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs Recruiting NCT02907359 Phase 3 Guadecitabine
39 Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Recruiting NCT00619879 Phase 3 Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients;Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies
40 Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission Active, not recruiting NCT01757535 Phase 3 300 mg Oral Azacitidine;Placebo
41 Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts Active, not recruiting NCT01241500 Phase 3 ON 01910.Na
42 Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Active, not recruiting NCT01928537 Phase 3 rigosertib sodium
43 Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Active, not recruiting NCT00843882 Phase 3 Lenalidomide
44 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
45 Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) Terminated NCT00109538 Phase 3 Lonafarnib
46 Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis Terminated NCT01749111 Phase 3 ARM A Cyclophosphamide;ARM B Calcineurin inhibitor and methotrexate
47 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
48 Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases Terminated NCT00450450 Phase 3
49 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
50 Lenalidomide in Patients With Chronic Myelomonocytic Leukemia Unknown status NCT01368757 Phase 1, Phase 2 Revlimid

Search NIH Clinical Center for Chronic Myelomonocytic Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Chronic Myelomonocytic Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Chronic Myelomonocytic Leukemia:
Hemacord�, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Embryonic/Adult Cultured Cells Related to Chronic Myelomonocytic Leukemia:
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD�) PMIDs: 9828244
Sources

Genetic Tests for Chronic Myelomonocytic Leukemia

About this section

Genetic tests related to Chronic Myelomonocytic Leukemia:

# Genetic test Affiliating Genes
1 Chronic Myelomonocytic Leukemia 29
Sources

Anatomical Context for Chronic Myelomonocytic Leukemia

About this section

MalaCards organs/tissues related to Chronic Myelomonocytic Leukemia:

41
Myeloid, Bone, Bone Marrow, Monocytes, T Cells, Neutrophil, Liver
Sources

Publications for Chronic Myelomonocytic Leukemia

About this section

Articles related to Chronic Myelomonocytic Leukemia:

(show top 50) (show all 638)
# Title Authors Year
1
Chronic subdural collection overlying an intra-axial hemorrhagic lesion in chronic myelomonocytic leukemia: special report and review of the literature. ( 29658352 )
2018
2
Evaluation by Flow Cytometry of Mature Monocyte Subpopulations for the Diagnosis and Follow-Up of Chronic Myelomonocytic Leukemia. ( 29707521 )
2018
3
Posaconazole-Induced Adrenal Insufficiency in a Case of Chronic Myelomonocytic Leukemia. ( 29568655 )
2018
4
So-called "blast phase" of chronic myelomonocytic leukemia: a plea for uniform terminology. ( 29955129 )
2018
5
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. ( 29728305 )
2018
6
A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XN<sup>TM</sup>analyzers in routine laboratory practice. ( 29310473 )
2018
7
The 2016 WHO versus 2008 WHO Criteria for the Diagnosis of Chronic Myelomonocytic Leukemia. ( 29797820 )
2018
8
KIT D816V- chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation. ( 29151134 )
2018
9
Chronic myelomonocytic leukemia with central nervous system involvement. ( 29322838 )
2018
10
Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. ( 29749401 )
2018
11
Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report. ( 29731877 )
2018
12
Characterization of chronic myelomonocytic leukemia with TP53 mutations. ( 29908419 )
2018
13
Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates. ( 29582697 )
2018
14
Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. ( 29596070 )
2018
15
Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. ( 29878489 )
2018
16
CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia. ( 29600428 )
2018
17
Leukemia cutis in a patient with chronic myelomonocytic leukemia. ( 29288601 )
2018
18
Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis. ( 29757120 )
2018
19
Evolving Understanding of Chronic Myelomonocytic Leukemia: Implications for Future Treatment Paradigms. ( 29891120 )
2018
20
Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia. ( 29227812 )
2018
21
EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. ( 29358618 )
2018
22
The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS. ( 29775844 )
2018
23
Chronic Myelomonocytic Leukemia following Multicentric Castleman Disease. ( 29607228 )
2018
24
Favorable evolution of lung interstitial disease in a patient with chronic myelomonocytic leukemia treated with azacitidine. ( 29170809 )
2018
25
DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features. ( 29160764 )
2018
26
Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia. ( 29368535 )
2018
27
Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective. ( 29588547 )
2018
28
A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. ( 29712989 )
2018
29
Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. ( 30190511 )
2018
30
Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients. ( 30105755 )
2018
31
Alteration in the Cytokine Secretion of Bone Marrow Stromal Cells from Patients with Chronic Myelomonocytic Leukemia Contribute to Impaired Hematopoietic Supportive Activity. ( 30123289 )
2018
32
Current management of patients with chronic myelomonocytic leukemia. ( 30169461 )
2018
33
Emerging utility of flow cytometry in the diagnosis of chronic myelomonocytic leukemia. ( 30176385 )
2018
34
Cardiovascular disease in chronic myelomonocytic leukemia: do monocytosis and chronic inflammation predispose to accelerated atherosclerosis? ( 30182347 )
2018
35
Chronic Myelomonocytic Leukemia Mimicking Invasive Fungal Rhinosinusitis. ( 30234474 )
2018
36
A Case of Synchronous Bone Marrow Chronic Myelomonocytic Leukemia (CMML) and Nodal Marginal Zone Lymphoma (NMZL). ( 30254190 )
2018
37
Recent Updates on Chronic Myelomonocytic Leukemia. ( 30311069 )
2018
38
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. ( 30328139 )
2018
39
Application of immunophenotypic analysis in distinguishing chronic myelomonocytic leukemia from reactive monocytosis. ( 30334354 )
2018
40
Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate. ( 30367142 )
2018
41
Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia. ( 30367269 )
2018
42
Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system. ( 30424699 )
2018
43
Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis. ( 30429467 )
2018
44
Chronic myelomonocytic leukemia presenting as upper limb gangrene. ( 30430087 )
2018
45
Utility of JAK2 V617F allelic burden in distinguishing chronic Myelomonocytic leukemia from primary myelofibrosis with Monocytosis. ( 30447300 )
2018
46
Increased cardiovascular comorbidities in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia presenting with systemic inflammatory and autoimmune manifestations. ( 30502853 )
2018
47
Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. ( 29023992 )
2018
48
High sensitivity of the Hematoflowâ„¢ solution for chronic myelomonocytic leukemia screening. ( 29108126 )
2018
49
Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. ( 29475821 )
2018
50
Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. ( 29557496 )
2018
Sources

Variations for Chronic Myelomonocytic Leukemia

About this section

Copy number variations for Chronic Myelomonocytic Leukemia from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 160282 22 11800000 24300000 Translocation Chronic myelomonocytic leukemia
2 228217 7 75001344 75206215 Translate HIP1 Chronic myelomonocytic leukemia
3 247204 9 129300000 140273252 Translocation Chronic myelomonocytic leukemia
Sources

Expression for Chronic Myelomonocytic Leukemia

About this section
Search GEO for disease gene expression data for Chronic Myelomonocytic Leukemia.
Sources

Pathways for Chronic Myelomonocytic Leukemia

About this section

Pathways related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Developmental Biology 66
Show member pathways
 13.37 CSF2 EZH2 JAK2 KDM6A KIT NF1
2
Akt Signaling 64
Show member pathways
 13.31 CSF1 CSF2 CSF3R FLT3 JAK2 KIT
3
PAK Pathway 64
Show member pathways
 13.18 CSF1 CSF2 CSF3R JAK2 KIT PDGFRB
4
Cytokine Signaling in Immune system 66
Show member pathways
 12.92 CSF1 CSF2 CSF3R FLT3 JAK2 KIT
5
PI3K-Akt signaling pathway 37
Show member pathways
 12.85 CSF1 CSF3R FLT3 JAK2 KIT PDGFRB
6
Endometrial cancer 37
Show member pathways
 12.7 CSF2 FLT3 KIT PDGFRB PTPN11 RUNX1
7
MAPK signaling pathway 37 1
12.65 CSF1 FLT3 KIT NF1 PDGFRB
8
Pathways in cancer 37
12.63 CSF3R FLT3 JAK2 KIT PDGFRB RUNX1
9
Ras signaling pathway 37
Show member pathways
 12.52 CSF1 FLT3 KIT NF1 PDGFRB PTPN11
10
Chromatin Regulation / Acetylation 4
12.31 DNMT3A EZH2 KDM6A TET2
11
JAK-STAT signaling pathway (KEGG) 37
Show member pathways
 12.22 CSF2 CSF3R JAK2 PDGFRB PTPN11
12
Tyrosine Kinases / Adaptors 4
11.97 FLT3 JAK2 KIT PDGFRB
13
Transcriptional misregulation in cancer 37
11.92 CSF2 ETV6 FLT3 KDM6A RUNX1
14
VEGF Pathway (Tocris) 61
Show member pathways
 11.69 FLT3 KIT PDGFRB
15
Central carbon metabolism in cancer 37
11.56 FLT3 KIT PDGFRB
16
MECP2 and Associated Rett Syndrome 1
11.52 EZH2 NF1 TET2
17
Dendritic Cells Developmental Lineage Pathway 65
11.49 CSF1 CSF2 FLT3 KIT
18
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.42 CSF1 CSF2 CSF3R FLT3 KIT
19
Signaling events mediated by PTP1B 1
11.4 CSF1 JAK2 PDGFRB
20
Hematopoietic Stem Cell Differentiation 1
11.37 CSF1 CSF2 RUNX1
21
Hematopoietic cell lineage 37
11.01 CSF1 CSF2 CSF3R FLT3 KIT
22
G-protein signaling_Rap2B regulation pathway 22
10.91 CSF1 CSF2 FLT3 KIT PDGFRB
23
Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex 1
10.89 DNMT3A ETV6 FLT3
24
Development of pulmonary dendritic cells and macrophage subsets 1
10.72 CSF1 CSF2
Sources

GO Terms for Chronic Myelomonocytic Leukemia

About this section

Cellular components related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.53 ASXL1 DNMT3A ETV6 EZH2 FLT3 HIP1
2 receptor complex GO:0043235 9.26 CSF3R FLT3 KIT PDGFRB

Biological processes related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 FLT3 KIT PDGFRB PTPN11
2 chromatin organization GO:0006325 9.91 ASXL1 DNMT3A EZH2 JAK2 KDM6A TET2
3 positive regulation of cell migration GO:0030335 9.9 CSF1 JAK2 KIT PDGFRB
4 regulation of gene expression GO:0010468 9.89 CSF2 DNMT3A EZH2 KDM6A NF1
5 regulation of cell proliferation GO:0042127 9.88 CSF2 EZH2 KIT NF1
6 protein autophosphorylation GO:0046777 9.87 FLT3 JAK2 KIT PDGFRB
7 positive regulation of cell proliferation GO:0008284 9.87 CSF1 CSF2 EZH2 FLT3 JAK2 KIT
8 positive regulation of protein kinase B signaling GO:0051897 9.86 HIP1 KIT PDGFRB PTPN11
9 phosphatidylinositol phosphorylation GO:0046854 9.83 KIT PDGFRB PTPN11
10 response to estradiol GO:0032355 9.82 DNMT3A EZH2 PDGFRB
11 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.81 CSF1 FLT3 KIT PDGFRB
12 peptidyl-tyrosine phosphorylation GO:0018108 9.8 CSF2 FLT3 JAK2 KIT PDGFRB
13 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.78 FLT3 JAK2 KIT PDGFRB
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 CSF2 FLT3 JAK2 KIT
15 platelet-derived growth factor receptor signaling pathway GO:0048008 9.71 JAK2 PDGFRB PTPN11
16 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.7 FLT3 KIT PDGFRB
17 positive regulation of MAP kinase activity GO:0043406 9.67 EZH2 FLT3 KIT PDGFRB
18 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.65 CSF1 CSF2
19 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.64 JAK2 PDGFRB
20 interleukin-6-mediated signaling pathway GO:0070102 9.63 JAK2 PTPN11
21 megakaryocyte development GO:0035855 9.63 KIT PTPN11
22 MAPK cascade GO:0000165 9.63 CSF2 FLT3 JAK2 KIT NF1 PDGFRB
23 hematopoietic stem cell proliferation GO:0071425 9.62 ETV6 RUNX1
24 positive regulation of phospholipase C activity GO:0010863 9.62 KIT PDGFRB
25 dendritic cell differentiation GO:0097028 9.61 CSF2 FLT3
26 response to fluid shear stress GO:0034405 9.59 CSF2 PDGFRB
27 myeloid progenitor cell differentiation GO:0002318 9.58 FLT3 KIT
28 regulation of myeloid cell differentiation GO:0045637 9.43 CSF2 CSF3R RUNX1
29 hemopoiesis GO:0030097 9.35 ASXL1 CSF1 FLT3 KIT RUNX1
30 cytokine-mediated signaling pathway GO:0019221 9.17 CSF1 CSF2 CSF3R FLT3 JAK2 KIT
31 cell differentiation GO:0030154 10.09 CSF1 ETV6 FLT3 HIP1 JAK2 KIT

Molecular functions related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 ASXL1 CSF1 CSF2 CSF3R DNMT3A ETV6
2 chromatin binding GO:0003682 9.77 ASXL1 DNMT3A EZH2 KDM6A TOP1
3 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.73 DNMT3A ETV6 EZH2 KDM6A RUNX1 TOP1
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.58 KIT PDGFRB PTPN11
5 protein tyrosine kinase activity GO:0004713 9.55 CSF2 FLT3 JAK2 KIT PDGFRB
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.5 FLT3 KIT PDGFRB
7 insulin receptor substrate binding GO:0043560 9.46 JAK2 PTPN11
8 peptide hormone receptor binding GO:0051428 9.43 JAK2 PTPN11
9 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.02 CSF2 FLT3 JAK2 KIT PDGFRB
Sources

Sources for Chronic Myelomonocytic Leukemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....